BTIG lowered the firm’s price target on Gain Therapeutics (GANX) to $5 from $9 and keeps a Buy rating on the shares. In a broader research note previewing Q3 results for select biotech names, the firm is updating its assumptions and models for the company, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GANX:
- Eric Richman Resigns from Gain Therapeutics Board
- Gain Therapeutics price target raised to $7 from $5 at Maxim
- Unusually active option classes on open October 6th
- Gain Therapeutics presents initial data from Phase 1b study of GT-02287
- Gain Therapeutics begins GT-02287 Phase 1b extension study in Parkinson’s